On Friday, Shares of Ford Motor Co. (NYSE:F), lost -3.95% to $13.86.
One of the most iconic performance Mustang nameplates of all time the all-new Shelby® GT350R roared off the line recently at Ford’s Flat Rock Assembly Plant. The new GT350R Mustang is the most athletic Mustang ever, designed to tackle the world’s most challenging roads and race tracks while creating an exhilarating experience for the driver.
“This is a special day for all Mustang enthusiasts,” said Bill Ford, executive chairman, Ford Motor Company. “We have taken the GT350 formula to the next level of innovation, style and performance. Recently the legend continues.”
Ford Motor Company manufactures and distributes automobiles worldwide. The company operates through two sectors, Automotive and Financial Services. The Automotive sector develops, manufactures, distributes, and services vehicles, parts, and accessories.
Shares of Baxter International Inc. (NYSE:BAX), declined -3.36% to $38.28, during its last trading session.
The Company has revealed insider buying and selling activities to the Securities Exchange, According to the information revealed by the Securities and Exchange Commission in a Form 4 filing, the director of Baxter International Inc, Shapazian Carole J had sold 1,533 shares worth of $103,753 in a transaction dated May 22, 2015. In this transaction, 1,533 shares were sold at $67.68 per share.
In other news, Baxter International Inc. (BAX) and Water Street Healthcare Partners declared the United States Food and Drug Administration (FDA) has approved CEFAZOLIN Injection in GALAXY Container (2 g/100 mL), which is Baxter’s flexible container that uses the company’s proprietary aseptic filling manufacturing processes. CEFAZOLIN injection is a cephalosporin antibacterial indicated for preoperative prophylaxis treatment. When used for preoperative prevention, it may reduce the incidence of certain postoperative infections for high-risk patients undergoing surgical procedures. See below for full Indication and Important Risk Information.
”The availability of CEFAZOLIN 2 gram in an efficient, ready-to-use, flexible premix container that can improve pharmacy efficiency will provide additional supply options of an important antibiotic,” said Brik Eyre, president of Baxter’s Hospital Products business.
CEFAZOLIN injection has been on the FDA’s drug shortage list for more than one year due to high demand. Baxter anticipates launching CEFAZOLIN injection 2 gram frozen premix in its GALAXY container in the United States in the fourth quarter of 2015.
CEFAZOLIN injection 2 gram represents the first of nine molecules actively under development to provide healthcare providers needed injectable formulations of essential drugs frequently used in critical care settings through Baxter’s development partnership with Celerity Pharmaceuticals, LLC, a company of Water Street, a planned investor focused exclusively on the healthcare industry.
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Brent and US crude futures hit fresh 6-1/2-year lows on Monday to drop below the latest supports of $45 a barrel and $40 a barrel respectively as investors fretted that a slowing Chinese economy will lead to weaker demand amid a global supply surplus.
Brent oil was trading down $1.39 a barrel, or 3.06 per cent, at $44.07 as of 0617 GMT, after hitting an intraday low of $44.00, its lowest since March 2009. On Friday it ended $1.16, or 2.5 per cent, lower at $45.46 a barrel.
Oasis Petroleum Inc. (NYSE:OAS), ended its last trade with -4.76% loss, and closed at $9.20.
Oasis Petroleum Inc., an independent exploration and production company, focuses on the acquisition and development of unconventional oil and natural gas resources in the North Dakota and Montana regions of the Williston Basin.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
